SCHEMBL5227424

SCHEMBL5227424

CCOC(=O)CNCc1cccc(OCc2nc(-c3ccccc3)oc2C(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.52
PPARG P37231 17/20 0.45
PPARA Q07869 16/20 0.45
FFAR1 O14842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227314 0.80 PPARG (0.57) KDRPPARGPPARA
SCHEMBL14303868 0.80 FFAR1 (0.64) KDRPPARGPPARAFFAR1
SCHEMBL5229166 0.80 BCHE (0.62) FFAR1
SCHEMBL5226709 0.78 PPARG (0.55) PPARGPPARA
SCHEMBL13718735 0.76 PPARG (0.64) PPARGPPARA
SCHEMBL5224449 0.76 PPARA (0.49) PPARGPPARA
SCHEMBL5262048 0.75 PPARG (0.55) KDRPPARGPPARA
SCHEMBL11009182 0.75 SMN1; SMN2 (0.56) PPARGPPARAFFAR1
SCHEMBL5227489 0.75 PPARG (0.57) PPARGPPARA
SCHEMBL13718908 0.74 PPARG (0.69) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 KDR 4100/4885PPARG 399/4885PPARA 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.